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The use of proton pump inhibitors (PPIs) on prescription has increased over the last decade in 
Norway. PPIs are an important medication in the treatment of acid related disorders such as 
peptic ulcer disease, gastroesophageal reflux disease and Helicobacter Pylori (H. Pylori) 
infection. However, many previous studies have raised concern about the potential risk of 
gastric cancer following the use of PPIs. In this registry-based study we will investigate the 
association between use of PPI and Histamine-2 receptor antagonist (H2RA) and the risk of 
gastric cancer in Norway.  
Methods 
This population-based nested case-control study comprises all primary gastric cancer cases in 
Norway diagnosed between 2007 and 2015 at an age of 18-85 and registered in the Cancer 
Registry of Norway. Ten cancer free controls were matched to each case on birth year, sex 
and index date (date of diagnosis). PPI and H2RA drug exposure were retrieved from the 
Norwegian Prescription Database and modelled as binary use, long-term use, cumulative use 
and in an active comparator design. Moreover, we used a stratified cox regression adjusted for 
H. Pylori, residency, education, comorbidity and other drug use to assess the link between 
PPI and H2RA use and the risk of gastric cancer. 
Results 
Among 33 847 individuals in this study, we found an increased risk of gastric cancer among 
PPI users (HR=1.25, 95% Cl 1.13-1.37) and long-term PPI users (HR=1.18, 95% Cl 1.03-
1.36) in Norway. There was also a significant impact on gastric cancer among PPI users 
living in Northern Norway (HR=1.43, 95% Cl 1.27-1.61). However, the dose-response 
relationship for PPI and the corresponding results for H2RA were not associated with an 
increased risk of gastric cancer. In addition, there was no significant risk of gastric cancer 
when comparing PPI use directly to H2RA use in an active comparator design (HR=0.98, 





The association found between PPI use and the increased risk of gastric cancer was most 
likely due to confounding by indication like H. Pylori infection and other unobserved 
confounders. Observational studies adjusted for all relevant confounders and larger clinical 
studies with a longer follow-up are needed to establish or rule out a causal relationship 
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1 Introduction 
In 2020, approximately 10% of the Norwegian population received proton pump inhibitor 
(PPI) on prescription at least once (1). Several previous studies have reported that use of PPIs 
is associated with an increased risk of gastric cancer, while previous findings on the use of 
Histamine-2 receptor antagonist (H2RA) and gastric cancer risk has been inconsistent. This 
population-based nested case-control study is aimed to find the association between use of 
PPI and H2RA and the risk of gastric cancer in Norway.  
1.1 Gastric cancer 
Gastric cancer is a malignant tumor that develops from the lining of the stomach and is 
categorized as C16 according to the International Classification of Disease Tenth Revision 
(2). Gastric cancer occurs mainly in elderly whereas men are twice as likely to develop gastric 
cancer compared to women. In addition, 95% of all gastric cancers are adenocarcinomas (3). 
Gastric cancer is the sixth most common cancer and the fourth cause of cancer-related 
mortality in the world (4).  
In 2019, 440 individuals were diagnosed with gastric cancer (C16) in Norway, with 279 of 
them being men while 161 were women. The median age of gastric cancer diagnosis was 73, 
and there was twice as many gastric cancer cases in men compared to women. Hordaland 
followed by Trøndelag, Akershus and Oslo accounted for most of the cancer cases between 
2015 to 2019 among men. However, for both males and females, the incidence and mortality 
have been declining since 1965, and the survival has moderately increased over time (5). 
The cause of gastric cancer is estimated to result from a complex interaction between genetic 
predisposition, diet and infection (6). Up to 80% of non-cardia gastric cancer have been 
estimated to be caused by Helicobacter Pylori (H. Pylori) which cause an infection in the 
stomach (7). H. Pylori infection increases the risk of gastric cancer via the indirect and the 
direct effect (8). The indirect effect is through a chronic inflammatory process where 
persistent inflammation can lead to atrophic gastritis and peptic ulcer disease (PUD), which 
are well-known risk factors for developing gastric cancer (9, 10).  
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The direct effect is due to the toxic action of virulence factors from H. Pylori. These virulence 
factors can cause mutations of cell-cycle regulating genes and deficiencies in DNA repair 
mechanism. Studies in animals have also shown an increased mutation rate in gastric mucosa 
infected with H. Pylori (8).  
As for genetic predisposition, hereditary diffuse gastric cancer accounts for about 1-3% of 
cases, while familial gastric cancer are observed in about 10% of all the gastric cancer cases 
(6). The dietary factors that are associated with gastric cancer are high-salt and salt-preserved 
food (3). 
1.2 Drugs for acid related disorders 
Gastric acid produced from the parietal cells in the stomach plays a key role in digesting 
proteins from food. The function of parietal cell is to secrete intrinsic factor and hydrochloric 
acid which creates the acidic environment. The role of acetylcholine, gastrin and histamine is 
to stimulate the parietal cells to secrete hydrochloric acid and intrinsic factor, while 
somatostatin inhibits the secretion from parietal cells.  
If the gastric acid exposes into deeper tissues and cells in the stomach as a result from high 
levels of gastric acid, or weakening of the mucus layer in the stomach, it could lead to 
stomach ulcers or acid reflux symptoms. In contrast, if the levels of gastric acid are too low, it 
may impair the ability of digesting food. Therefore, the gastric acid levels and the protective 
mucus layer should be in balance to avoid stomach ulcers or reflux symptoms. 
The acidic environment in the stomach is also important to inhibit the growth of 
microorganisms, and thus helpful to prevent infections. Yet, H. Pylori can overcome the 
acidic environment to cause an infection by producing urea which leads to local alkalization 
and thereby protecting the bacteria from gastric acid (11). 
PPI and H2RA are drugs that inhibits the gastric acid secretion and have a similar indication 
of use. However, H. Pylori infection is an indication solely for PPI while the common 
indication for PPI and H2RA are PUD, gastroesophageal reflux disease (GERD), Zollinger-
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Regarding mechanism of these drugs, PPIs binds to proton pumps in the parietal cells and 
inhibits the proton pumps from releasing protons (H+ ions) into the lumen. As a result, PPI 
inhibits the final step of gastric acid secretion from a parietal cell regardless of acetylcholine, 
gastrin and histamine (14).  
Although the primary aim for H2RA is to inhibit the gastric acid as well, the mechanism of 
H2RA differs from PPIs. H2RA binds to Histamine-2 receptor on the parietal cell and 
prevents histamine from stimulating the parietal cells to secrete gastric acid (15). In contrast 
to PPI, H2RA inhibits an earlier step of gastric acid secretion. Nevertheless, acetylcholine and 
gastrin could still stimulate the parietal cell to secrete gastric acid and explains why PPI is a 
more potent drug than H2RA (figure 1).    
 
Figure 1 A simplified physiology of gastric acid secretion from parietal cells and the mechanism of action for PPIs 
and H2RAs. PPI, Proton Pump Inhibitor; H2RA, Histamine-2 Receptor Antagonist; H+, proton; Cl-, chloride ion; P, 
proton pump 
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1.3 The use of PPI and H2RA in Norway 
 
Figure 2 Proportion of PPI and H2RA users in Norway from 2004 to 2020. Over-the-counter drugs and the 
combination drug Vimovo (Naproxen and Esomeprazole) were not included (1). 
The number of PPI users on prescription have more than doubled since 2004 while the 
number of H2RA users on prescription have been decreasing in Norway (figure 2). In 2020, 
580 758 individuals received PPI on prescription at least once, which is approximately 10% 
of the Norwegian population. Within the same year, the proportion of PPI users increased 
with increasing age and most PPI users were females (figure 3). In addition, Northern Norway 
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Figure 3 Proportion of PPI users in 2020 by age and sex. PPI over-the-counter and the combination drug Vimovo 
(Naproxen and Esomeprazole) were not included (1). 
 
Figure 4 Proportion of PPI users in Norway from 2004 to 2020 by residency. PPI over-the-counter and the 
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1.4 PPI and H2RA use and gastric cancer 
The association between PPI use and the increased risk of gastric has been observed in several 
studies, especially in observational studies and in vivo studies as well. However, clinical 
studies do not support this hypothesis, though there have not been many clinical studies 
investigating this hypothesis in contrast to observational studies.  
As for observational studies, a meta-analysis from Qian-Yi Wan et al (16) concluded that 
long-term PPI use implied an approximately twofold risk for gastric cancer (OR=2.10, 95% 
Cl 1.10–3.09). Wan additionally categorized the risk into subgroups and found that 
participants with H. Pylori infection had an increased risk of gastric cancer (OR=5.01, 95% 
Cl -4.27-14.29).  
Another study found that long-term PPI user was associated with an increased risk of gastric 
cancer in subjects even after H. Pylori eradication therapy (HR=2.44, 95% Cl 1.42-4.20). 
Moreover, the study was able observe a clear dose-response relationship. They found that 
daily use of PPIs was associated with a higher risk of gastric cancer (HR=4.55, 95% Cl 1.12-
18.52) compared to weekly to < daily users (HR=2.43, 95% Cl 1.37-4.31) (17).  
Potential bias and confounder such as immortal time bias, latency bias and Vitamin B12 
deficiency among PPI users were mentioned that could affect the results of Cheung et al study 
(18, 19). However, one study included immortal time bias and latency bias and found that PPI 
use was still associated with an increased odds of gastric cancer (20), while the potential 
vitamin B12 confounder still remains unknown.  
Previous studies that are probably relevant in a Norwegian context due to similar dietary 
habits and prevalence of H. Pylori is the Swedish study and Danish study. The Swedish study 
concluded that maintenance use of PPI was associated with an increased risk of gastric cancer 
(SIR=3.38, 95% Cl 3.25-3.53), while the Danish study observed an increased risk of gastric 
cancer among individuals who have received more than 15 prescriptions on PPI (IRR=2.1, 
95% Cl 1.0-4.7). The Swedish study did also stratify the analysis into different indications 
and observed that the risk was especially increased in participants with H. Pylori infection 
(SIR=9.76, 95% Cl 8.87-10.71) and PUD (SIR=8.75, 95% Cl 8.12-9.41). Regarding H2RA, 
none of the two studies observed an increased risk of gastric cancer among H2RA users (21, 
22).  
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A recent observational study included H2RA use in the analysis and observed an increased 
risk of gastric cancer among H2RA users (OR=1.44, 95% Cl 1.16-1.80). However, they 
suggested that the association between use of PPI and H2RA and the increased risk of gastric 
cancer was sensitive to the duration of lag-time used in the analysis. When the author applied 
1-year lag time, the risk of gastric cancer was increased. But when the author used 2-year lag 
time, the association was attenuated, and thus concluded that they observed little consistent 
evidence on PPI use and the increased risk of gastric cancer (23).  
Furthermore, some studies have investigated the duration-response relationship. All of these 
studies revealed a similar tendency, which is decreased risk estimates of gastric cancer when 
the duration of PPI use increases (16, 21, 23). From Wan’s meta-analysis, the risk estimates 
of using PPI a year or less (OR=4.13, 95% Cl -1.80-10.07) was higher when compared to 
using PPI for 3 or more years (OR=1.01, 95% Cl 0.51-1.50). The authors from the Swedish 
study suggested that the decreased risk estimates indicated that long-term use of PPI probably 
protected against risk factors (H. Pylori and PUD) for developing gastric cancer. 
In contrast to observational studies, clinical studies do not support the hypothesis between 
maintenance PPI use and gastric cancer development. In a meta-analysis which investigated 
six randomized controlled trials (RCT), the authors concluded that maintenance PPIs therapy 
was not associated with an increased gastric atrophic change or Enterochromaffin-like (ECL) 
cell hyperplasia. However, the authors stated that due to their protocol of the review, they 
excluded some potentially useful data from prospective non-randomized trials which had 
longer duration of follow-up that might be more valuable than RCTs in the assessment of 
premalignant lesions. However, this meta-analysis only assessed for long-term PPI use and 
the risk for premalignant lesions which is involved in the gastric cancer development. 
As for the potential carsinogenic mechanism of PPIs and H2RA, there have been two in vivo 
studies in 1985 and 1986. Findings from these studies showed that Loxitidine (H2RA) and 
Omeprazole (PPI) induced gastric mucosa neoplasia among rodents, and thereby suggested 
that PPI and H2RA could play a role in the development of gastric cancer (24, 25).  
Although in vivo studies were conducted in animals, hypergastrinemia and non-H. Pylori 
bacterial overgrowth has been addressed as potential carcinogenic mechanisms of PPIs among 
humans (26). Hypergastrinemia is a compensatory increase in gastrin production as a negative 
feedback due to the suppression of gastric acid production (27). The increased level of gastrin 
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drives the hyperplasia of ECL cells in the oxyntic mucosa which can lead to the formation of 
neuroendocrine tumors (NETs) (28).  
Moreover, the lack of a gastric acid can lead to non-H. Pylori bacterial overgrowth in the 
stomach as a result of using PPIs. The overgrowth of non-H. Pylori bacteria in the stomach 
can lead to chronic inflammation and thus atrophic gastritis. It has been shown that non-H. 
Pylori bacterial overgrowth is a risk factor for atrophic gastritis (26, 29). 
To summarize these findings, the results of many previous observational studies and in vivo 
studies have suggested that there is an association between long-term use of PPI and gastric 
cancer or that PPI and H2RA could play an important role in gastric cancer development. 
Possible carcinogenic mechanism supports this hypothesis as well. However, clinical studies 
do not support the relationship between long-term PPI and the risk of gastric cancer 
development.  
In our study, the overall aim is to investigate if there is an association between PPI and H2RA 
use and risk of gastric cancer in a register-based study in an unselected population in Norway. 
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2 Aims and hypothesis 
The overall aim of this thesis is to evaluate whether there is an association between PPI and 
H2RA use and the risk of gastric cancer in a register-based study based on an unselected 
population. More specifically, we will investigate the following sub-aims: 
1. Description of clinical and geographical factors as well as PPI and H2RA use in the 
study population 
2. Evaluation of the association between the use of PPI and H2RA and the risk of gastric 
cancer adjusted for sex, age and date of diagnosis (by design) as well as H. Pylori, 
geography, education, comorbidity and other drug use  
3. Evaluation of the risk for gastric cancer when using PPI compared to H2RA in an 
active comparator design 
The public health perspective of identifying association between the use of PPI and H2RA 
and gastric cancer can reassure patients and prescriber about the safety of PPIs and H2RAs 
and promote their appropriate use, especially due to the increasing use of PPIs in Norway the 
last decade.   
 
Page 10 of 43 
3 Material and Methods 
3.1 Data sources  
The Norwegian population is covered by a publicly funded healthcare system. Several 
national administrative and disease registries have been established that may be linked using a 
unique individual identification number assigned to all inhabitants of Norway. These 
Norwegian registries give a good prerequisite to conduct true population-based studies of 
diseases efficiently within this framework.  
 
Figure 5 Data sources in the underlying study. ATC, Anatomical Therapeutic Chemical (30). 
All adults residing in Norway aged 18-85 with a primary diagnosis of gastric cancer (C16) 
diagnosed between 2007 and 2015 were obtained from the Cancer Registry of Norway 
(CRN). The CRN has recorded incident cases of cancer nationwide since 1953. The registry 
has been shown to have accurate and almost complete ascertainment of cancer cases (31).  
Information on the use of PPI and H2RA was provided by the Norwegian Prescription 
Database (NorPD). NorPD covers all prescription drugs dispensed to individuals in 
ambulatory care in Norway since 2004. The information also comprises the date, amount and 
county of the dispensed drug (32). 
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CRN and NorPD are the main data sources in this registry-based study. In addition, the 
Norwegian Patient Registry (NPR) provided data on comorbidity while Statistics Norway 
(SSB) gave information on education. In this case, we will use variables from all of these data 
sources to adjust for potentially confounding factors (figure 5). 
The linkage process was organized like this: The CRN sent the Norwegian individual 
identification number and an internal identification number to all registries involved. All 
registries linked their information to the identification number and sent their information 
together with the internal identification number to the NorPD, which pseudonomized the data 
before sending it back to CRN.  
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3.2 Study design and study population 
Experimental studies such as systematic reviews and meta-analyses are at the top of the 
evidence pyramid followed by experimental studies and observational studies such as cohort, 
case-control and nested case-control studies (33). Observational studies do not introduce an 
intervention or randomize the exposure and non-exposure group by chance in contrast to 
RCTs (experimental studies).  
In this observational study, we used a nested case-control study design with risk-set sampling. 
A nested-case control study is a variation of case-control study where the cases and controls 
are drawn within an underlying cohort. The advantages of using a nested case-control study 
are that we can avoid or minimize selection, recall and information bias. The limitation of a 
nested case-control study is that the observed results only reveal an association only, and thus 
do not imply causal effects due to the possibilities of unknown or unobserved confounders. 
The study population comprises all gastric cancer cases, diagnosed with gastric cancer (C16) 
in Norway between January 1st, 2007 and December 31st, 2015 and aged 18 to 85. Ten cancer-
free controls were matched to each case with respect to birth year, sex and index date (date of 
diagnosis).  
The control group is cancer-free individuals until index date but might get cancer later in life. 
By choosing ten controls per case, the uncertainty of the estimates are only negligibly larger 
than the uncertainty of the estimates in a cohort study (30).  
3.3 Drug exposure 
All drug exposure was based on prescriptions dispensed from 2004 and up to 1 year before 
the index date. Drug use was defined in two different ways: the crude exposure defining 
(long-term) users and non-users based on the total number of prescriptions and the cumulative 
exposure based on the cumulative DDDs.  
We excluded PPI and H2RA use within 12 months before index date to avoid reverse 
causation as drug intake during this period could possibly be induced by early cancer 
symptoms. Reverse causation is when drug use is associated with cancer risk, but in the 
opposite direction of what we expect. For example, we expect that drug use will cause cancer, 
but as for reverse causation, cancer will cause the use of drug instead. In other words, PPI and 
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H2RA could be prescribed to treat early symptoms of a gastric cancer disease which is not yet 
diagnosed.   
3.3.1 Users vs. Non-users 
Drug users were defined as at least one prescription of PPI or H2RA between 2004 and up to 
one year before index date. Non-users are defined as not having used or received PPI or 
H2RA on prescription between 2004 and up to 1 year before index date. 
3.3.2 Long-term vs. Non-users 
Long-term drug use was defined based on the number of prescriptions filled from 2004 to one 
year before index date. Long-term use was defined as at least 8 prescription and short-term 
use as 1-7 prescriptions. Long-term use of PPI and H2RA corresponds to approximately two 
years of use assuming a duration of 3 months per prescription filled. Non-users are defined as 
not having used or received PPI or H2RA on prescription between 2004 and up to 1 year 
before index date. 
3.3.3 Cumulative dose 
The dose-response relationship was also evaluated for PPI and H2RA. Cumulative DDD, 
which is a variable that summarizes the total DDD for all prescriptions within the inclusion 
period, was grouped into a categorical variable.  
All drug users were thus categorized into one out of 5 groups as shown in table 1. The 
reference group (1st quintile group) is the group of users with the lowest use and received at 
least one prescription of PPI or H2RA. The DDD limits for each group are presented in table 
1 as well. The 2nd to the 5th quintile groups were compared to the reference group to assess the 
dose-response relationship.  
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Table 1 The DDD limits for each quintile groups. DDD; Defined daily dose; PPI, Proton Pump Inhibitor; H2RA, 
Histamine-2 Receptor Antagonist 
 
We considered to analyze the cumulative DDD as a continuous variable, but this would have 
led to a mass distribution problem given mainly non-users. Excluding non-users from the 
analysis would lead to a dramatic decrease in power as all sets with a non-user case would be 
excluded. Moreover, not conditioning on matching anymore would introduce a bias because 
of an oversampling of cases. Thus, we decided to group the drug users in 5 user categories 
(non-users being the 6th category) and used the lowest user category as a reference in the 
analysis when evaluating dose-response relationships. 
  
Quintile DDD limits for PPI DDD limits for H2RA 
1 4-27 (4 is the lowest dose) 3-15 (3 is the lowest dose) 
2 28-11 16-30 
3 12-427 31-90 
4 428-1256 91-410 
5 1257-9036 411-9920 
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3.3.4 ATC classification 
Anatomical Therapeutic Chemicals (ATC) classification is a system that is used to classify 
the active ingredients of drugs according to which organ or system the active substance act, 
and their therapeutic, pharmacological and chemical properties. The active substances are 
thus classified in five different levels. The 1st level is classified into anatomical main group, 
2nd level is the therapeutic subgroup, 3rd level the pharmacological subgroup and the 4th and 
5th level is the chemical- subgroup and substance (34). 
Given the ATC code A02B C02 as an example, the 2nd level comprises drugs for acid related 
disorders (ATC code: A02) while the 4th level is proton pump inhibitors (ATC code: A02 BC) 
(table 2). 
Table 2 ATC codes for PPI and H2RA. ATC, Anatomical Therapeutic Chemical (35). 
ATC levels ATC code Active substance 
ATC 5th level for PPI 
A02B C01 Omeprazol 
A02B C02 Pantoprazol 
A02B C03 Lansoprazol 
A02B C05 Esomeprazol 
ATC 5th level for H2RA 
A02B A01 Cimetidine 
A02B A02 Ranitidine 
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3.4 Covariates 
We will adjust for H. Pylori infection by identifying patients within the study who had 
undergone H. Pylori eradication therapy. From the Norwegian guidelines of treating H. Pylori 
infection, the therapy consists of treating with two of three antibiotics simultaneously 
(amoxicillin, metronidazole and clarithromycin; ATC codes: J01CA04, J01XD01 and 
J01FA09) plus a PPI (36). The method we used to identify H. Pylori patients was to include 
patients who received prescription on two of three antibiotics used in eradication therapy 
simultaneously or within the same month. The same method was used in the Danish study 
(22). 
In addition, we adjusted for comorbidity measured by a modified version of Charlson 
Comorbidity Index (CCI) using the Patient Registry Index (PRI). The CCI is an approach to 
measure one-year mortality in patients who have may have a range of diseases based on the 
International Classification of Diseases. Each comorbidity is weighted differently (1 to 6), 
and CCI also takes the severity of a comorbidity into consideration. As an example, PUD is 
associated with lower weigh in contrast to malignant tumor which is associated with a higher 
weight. The scores are summed up to predict the one-year mortality for a patient. A higher 
score indicates to a higher risk of mortality or resource use while a lower score indicates to a 
decreased risk of mortality (37, 38). 
The modified version of The CCI is an updated version of comorbidity index using the 
Norwegian PRI where the comorbidity index is weighted differently, and the conditions are 
either changed or adapted compared to conventional CCI. As an example, when age was 
considered in PRI, the comorbidity score was reduced for patients older than 50 years. PRI 
was also marginally better than the CCI to predict one-year mortality. Moreover, PRI are 
based on a more recent data in contrast to the CCI, and are thus more representative to the 
general population (39). All comorbidities (except cancer) of a patient up to two years before 
the index date were taken into consideration. 
Education provided by SSB was also taken into consideration. We were able to adjust 
education into five different categories which are the primary/lower secondary, upper 
secondary, undergraduate, graduate/postgraduate and no education/missing. The education 
groups were compared to primary/lower secondary as a reference 
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Long-term use of other medications (other drug use), defined as whether the patients are long-
term user of drugs from other drug groups than the ATC4-level of PPI and H2RA. 
Residency was categorized according to the four health regions in Norway, which are North, 
Mid, West and South-East. The cases were categorized into residency by using information 
from the CRN, while the information for the controls was retrieved from the NorPD. The 
regions were compared to the South-East as a reference.  
3.5 Statistical Methods 
3.5.1 Stratified Cox regression 
Given this nested case-control design, we applied a stratified Cox regression and received 
Hazard ratios (HRs), 95% confidence intervals (CIs) and corresponding p-values to evaluate 
the association between PPI/H2RA use and the risk of gastric cancer.  
HR refers to the ratio between the hazard rate among the exposure group versus the hazard 
rates among the non-exposure group and can in our case be interpreted as the risk of gastric 
cancer in the drug group compared to non-user group. For example, HR above 1 indicates that 
PPI or H2RA use is associated with an increased risk of gastric cancer while a HR below 1 
indicates a protective association. 
We chose HRs instead of odds ratios because we have a timeline in addition to the binary 
outcome, since we require the controls to be event-free at the time of cancer diagnosis of the 
case (time-matched controls). Thus, we used a stratified Cox regression instead of a logistic 
regression model, which makes HR a better estimate compared to a traditional case-control 
study where the outcome is binary within a pre-defined time frame.   
Interesting signals for PPI/H2RA use and gastric cancer will be defined based on p values, 
which combine information from the effect and sample size, variation in the data and will be 
compared to the type-I-error threshold α=0.05. Associations with p-values below this 
threshold were considered to be significant associations.  
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3.5.2 Test for Association 
To assess the PPI and H2RA use and gastric cancer risk, we will evaluate this association in 
four different analyses: binary drug use, long-term use, cumulative DDD and active 
comparator. Briefly, drug use and long-term use were compared to non-users while 
cumulative DDD was compared to the lowest use or at least one prescription of PPI/H2RA. 
Age, sex and index date are adjusted by design in all analysis. Finally, we will also adjust for 
H. Pylori, residency, education, comorbidity and other drug use.  
Moreover, due to the same indication of use for PPI and H2RA, there will be individuals that 
have used both PPI and H2RA. For example, some individuals may have tried H2RA first 
without effect, and then changed to the more potent PPIs. Thus, we will adjust for H2RA use 
when assessing the association between PPI use and gastric cancer risk and vice versa.  
H2RA was used as an active comparator to evaluate the association between PPI use and the 
risk of gastric cancer compared to H2RA use. As drug users might be different than non-users 
in many ways, confounding by indication can potentially bias the analyses. Thus, in the active 
comparator analysis we aim to compare PPI users with H2RA users when evaluating the 
association with risk of gastric cancer. PPI and H2RA use were thus compared between 
patient who had similar symptoms or diagnoses such as PUD or GERD. Figure 6 illustrates 
confounding by indication in our association analyses.  
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Figure 6 The effect of confounding by indication on the association between PPI and H2RA and gastric cancer. 
GERD, Gastroesophageal Reflux Disease; PUD, Peptic Ulcer Disease 
 
3.5.3 Descriptive statistics 
We presented results in tables and figures. Moreover, we presented percentage and 
median/Interquartile Range (IQR). IQR is the range between the lower and upper quartile 
when values are ordered from lowest to highest, and median is the value that separates the 
higher half from the lower half equally for a data set or a population. These quantities are 
robust against outliers.  
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4 Ethics 
This study was approved by the Regional Ethical Committee (2016/352 Identifikasjon av 
karsinogene og kjemopreventive effekter av reseptpliktige legemidler) and the Norwegian 
data protection authority.  
Furthermore, NorPD is a pseudonymized register which means that all birth numbers and 
health personnel number is replaced with a unique pseudonym for each individual in the study 
population so that they cannot be identified (40). 
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5 Results 
5.1 Basic characteristics 
In total there were 33 847 Norwegian individuals in this study, with 3 077 of them being 
cancer cases and 30 770 controls. Age (median 69; IQR 60-77) and sex (64% men) were 
equally distributed among gastric cancer and controls. In contrast, there was a higher 
percentage of cancer cases being H. Pylori positive (4%) and a higher percentage of cancer 
cases living in Western, Mid and Northern Norway (50%) when compared to controls (43%). 
There was also a higher percentage of comorbid patients among cancer cases (17%) and 
individuals using other drugs (70%) when compared to controls (table 3). 
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Table 3 Characteristics of gastric cancer cases and controls. H. Pylori, Helicobacter Pylori; Q1, Median of lower 
half; Q3, Median of upper half. 







Median - 69 69 
Q1, Q3 - 60, 77 60, 77 
Sex 
Female 12 210 (36%) 1110 (36%) 11 100 (36%) 
Male 21 637 (64%) 1967 (64%) 19 670 (64%) 
H. Pylori 
Negative  33 420 (99%) 2964 (96%) 30 456 (99%) 
Positive 427 (1%) 113 (4%) 314 (1%) 
Region of 
residence 
South-East Norway 18 356 (54%) 1501 (49%) 16 855 (55%) 
Western Norway 6557 (19%) 656 (21%) 5901 (19%) 
Mid Norway 4906 (14%) 495 (16%) 4411 (14%) 
Northern Norway 3464 (10%) 415 (13%) 3049 (10%) 
Unknown/missing region 564 (2%) 10 (0.3%) 554 (2%) 
Education 
Primary/lower secondary 10 260 (30%) 1105 (36%) 9155 (30%) 
Upper secondary 15 434 (46%) 1418 (46%) 14 016 (46%) 
Undergraduate 5334 (16%) 367 (12%) 4967 (16%) 
Graduate/postgraduate 2157 (6%) 125 (4%) 2032 (7%) 
No education/missing 662 (2%) 62 (2%) 600 (2%) 
Comorbidity 
0 29 031 (86%) 2537 (82%) 26 494 (86%) 
1-2 3180 (9%) 345 (11%) 2835 (9%) 
>2 1636 (5%) 195 (6%) 1441 (5%) 
Other drug use 
No 11 229 (33%) 938 (30%) 10 291 (33%) 
Yes 22 618 (67%) 2139 (70%) 20 479 (67%) 
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5.2 Drug use 
Out of 33 847 study participants, there were 8 398 (25%) drug users in this study, more 
specifically 6 300 (19%) PPI users and 2 098 (6%) H2RA users. Among all PPI users, 1 084 
(17%) individuals have also used H2RA while 5 216 (83%) are separate PPI users. As for 
H2RA users, more than half of H2RA users (1 014 individuals, 52%) have also used PPI. 
There were more long-term users (8+ prescriptions) among cases than controls (11% vs. 8%). 
This trend is also visible in PPI and H2RA users separately (table 4).  
Table 4 Characteristics of PPI and H2RA users. PPI, Proton Pump Inhibitor; H2RA, Histamine-2 Receptor 
Antagonist. 
 
Total (%) PPI (%) H2RA (%) 
Numbers of drug use dispensed on prescription (N=33 847) 
Non-users 25 449 (75%) 27 547 (81%) 31 749 (94%) 
1  2523 (7%) 1644 (5%) 879 (3%) 
2-7  2961 (9%) 2210 (7%) 751 (2%) 
8+ 2914 (9%) 2446 (7%) 468 (1%) 
Numbers of drug use dispensed on prescriptions among cancer (N=3077) 
Non-users 2071 (67%) 2324 (76%) 2824 (92%) 
1 314 (10%) 211 (7%) 103 (3%) 
2-7 358 (12%) 266 (9%) 92 (3%) 
8+ 334 (11%) 276 (9%) 58 (2%) 
Numbers of drug use dispensed on prescriptions among controls (N=30 770) 
Non-users 23 378 (76%) 25 223 (82%) 28 925 (94%) 
1 2209 (7%) 1433 (5%) 776 (3%) 
2-7 2603 (8%) 1944 (6%) 659 (2%) 
8+ 2580 (8%) 2170 (7%) 410 (1%) 
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Figure 7 presents the number of PPI and H2RA prescriptions dispensed among gastric cancer 
and controls. Among the drug users, we identified 1 320 (16%) individuals with 8-14 
prescription, 821 (10%) individuals with 15-24 prescriptions, 692 (8%) with 25-49 
prescription and 81 (1%) who received more than 49 prescriptions on either PPI or H2RA. 
 
Figure 7 Number of PPI or H2RA dispensed on prescription among gastric cancer and controls. PPI, Proton 
Pump Inhibitor; H2RA, Histamine-2 Receptor Antagonist. 
  
1 2-7 8-14 15-24 25-49 >49 1 2-7 8-14 15-24 25-49 >49
PPI H2RA
Controls 1433 1944 962 631 517 60 776 659 198 112 84 16
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5.3 Other risk factors and PPI and H2RA use  
The median age among H2RA users (median 72; IQR 63-79) was slightly higher when 
compared to PPI users (median 71; IQR 63-78), while there were a higher percentage of men 
(61%) among PPI users compared to H2RA users (57%). The existence of H. Pylori infection 
was verified in 5% (4%) of all PPI (H2RA) users. There was a higher percentage of H2RA 
users (54%) living in Western, Mid and Northern Norway when compared to PPI users 
(47%). We also identified a higher percentage of comorbidities among PPI users (28%) in 
comparison to H2RA users (25%). As a result, use of other drugs than PPI/H2RA was equally 
distributed between PPI and H2RA users (84%) (table 5).  
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Table 5 Characteristics of drug users and risk factors. PPI, Proton Pump Inhibitor; H2RA, Histamine-2 Receptor 








   Median 71 72 
   Q1, Q3 63, 78 63, 79 
Sex 
   Female 2479 (39%) 908 (43%) 
   Male 3821 (61%) 1190 (57%) 
H. Pylori 
   Negative 5978 (95%) 2023 (96%) 
   Positive 322 (5%) 75 (4%) 
Region of 
residence 
   South-East 3361 (53%) 967 (46%) 
   West 1236 (20%) 429 (20%) 
   Mid 896 (14%) 356 (17%) 
   North 807 (13%) 346 (17%) 
   Missing 0 (0%) 0 (0%) 
Education 
   Primary/lower secondary 2252 (36%) 800 (38%) 
   Upper secondary 2939 (47%) 955 (46%) 
   Undergraduate 810 (13%) 243 (12%) 
   Graduate/postgraduate 222 (4%) 72 (3%) 
   No education/missing 77 (1%) 28 (1%) 
Comorbidity 
   0 4557 (72%) 1577 (75%) 
   1-2 1068 (17%) 332 (16%) 
   >2 675 (11%) 189 (9%) 
Other drug use 
   No 1018 (16%) 330 (16%) 
   Yes 5282 (84%) 1768 (84%) 
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5.4 Association of PPI use and risk of gastric cancer 
In this study we found a significant impact of PPI use (HR=1.25, 95% Cl 1.13-1.37) and long-
term use (HR=1.18, 95% Cl 1.03-1.36) on the risk of gastric cancer. However, we did not 
observe a dose-response relationship between PPI use and gastric cancer risk. When 
compared to the group with the lowest dose, there were no significant changes with respect to 
the risk of gastric cancer for higher dose groups (quintile 2-5). The trend effects for the 3rd to 
5th quintile were stable (HRs=0.84-0.86) (table 6).  
Table 6 Association between PPI use and the risk of gastric cancer. HR, Hazard ratio; Cl, Confidence interval; 
PPI, Proton Pump Inhibitor. 
  HR* 95% Cl* P-Value* 
Drug use 
vs. non-use 
Non-use 1.00 - - 




Non-use 1.00 - - 
1 prescription 1.37 1.17-1.60 7.54·10-5 
2-7 prescriptions 1.23 1.07-1.42 4.55·10-3 
8+ prescriptions 1.18 1.03-1.36 0.0199 
Dose-response 
relationship 
Quintile 1 1.00 - - 
Quintile 2 1.08 0.85-1.36 0.533 
Quintile 3 0.84 0.66-1.07 0.155 
Quintile 4 0.86 0.67-1.09 0.210 
Quintile 5 0.86 0.68-1.10 0.234 
*The presented results are adjusted for H2RA use, H. Pylori, region of residence, education, 
comorbidity and other drug use 
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5.5 Association of H2RA use and risk of gastric cancer 
Overall, we observed an increased risk trend for gastric cancer among H2RA users (HR=1.14; 
95% Cl: 0.99-1.32). However, this result was not significant. Similarly, the results for long-
term H2RA users and the dose-response relationship were not significant either. There was no 
visible trend in the effects (HRs) of higher dose drug use (quintile 2-5) when comparing to the 
group of lowers drug use (table 7).  
Table 7 Association between H2RA use and the risk of gastric cancer. HR, Hazard ratio; Cl, Confidence interval; 
H2RA, Histamine-2 Receptor Antagonist. 
  HR* 95% Cl* P-Value* 
Drug use 
vs. non-use 
Non-use 1.00 - - 




Non-use 1.00 - - 
1 prescription 1.12 0.90-1.39 0.297 
2-7 prescriptions 1.15 0.91-1.44 0.241 
8+ prescriptions 1.18 0.89-1.57 0.252 
Dose-response 
relationship 
Quintile 1  1.00 - - 
Quintile 2 0.91 0.60-1.38 0.655 
Quintile 3 0.87 0.58-1.32 0.513 
Quintile 4 1.12 0.76-1.67 0.569 
Quintile 5 0.73 0.47-1.12 0.152 
*The presented results are adjusted for PPI use, H. Pylori, region of residence, education, comorbidity 
and other drug use 
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In summary, PPI use and long-term use were significantly associated with an increased risk of 
gastric cancer. However, we did not observe a dose-response relationship. Despite the fact 
that there was a trend for H2RA use associated to an increased risk of gastric cancer, this was 
not supported by the analyses considering long-term use and dose-response relationship 
(figure 8). 
 
Figure 8 Association between PPI and H2RA and the risk of gastric cancer. HR, Hazard ratio; Cl, Confidence 
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5.6 Active comparator analysis 
Table 8 presents the results of the active comparator analysis. We estimated the effect of 
separate PPI use versus separate H2RA use. The results revealed that the risk trend was not 
increased in PPI users compared to H2RA users (HR=0.98, 95% Cl 0.79-1.21).  
Table 8 Association between H2RA in an active comparator and the risk of gastric cancer. HR, Hazard ratio; Cl, 
Confidence interval; PPI, Proton Pump Inhibitor; H2RA, Histamine-2 Receptor Antagonist. 
 
 
HR* 95% Cl* p-Value* 
Active comparator 
H2RA use (no PPI use) 1.00 - - 
PPI use (no H2RA use)  0.98 0.79-1.21 0.839 
*The presented results are adjusted for H. Pylori, region of residence, education, comorbidity and other drug 
use 
 
Page 31 of 43 
5.7 The role of other risk factors on the association between 
drug use and gastric cancer 
The impact of other risk factors within the above association analyses was similar across all 
models applied (drug users, long-term users, dose-response and active comparator). Table 9 
presents the results for the other risk factors in the analysis investigating the association 
between PPI use and the risk of gastric cancer. We found that individuals with positive H. 
Pylori had a significant impact on gastric cancer (HR=2.99, 95% Cl 2.38-3.75).  
Residency in Northern Norway (HR=1.43, 95% Cl 1.27-1.61) also had a significant impact on 
gastric cancer followed by Mid (HR=1.24, 95% Cl 1.11-1.38) and Western Norway 
(HR=1.22, 95% Cl 1.11-1.35) when compared to South-East. Moreover, having a higher level 
of education (upper secondary or higher) was associated with a decreased risk of gastric 
cancer. In addition, we observed an increased risk of gastric cancer among comorbid PPI 
users (HR=1.08, 95% Cl 1.04-1.12) while we did not observe an impact of other drug use on 
the association between PPI and H2RA use and the risk of gastric cancer.  
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Table 9 Association between PPI use and the risk of gastric cancer adjusted for risk factors. HR, Hazard ratio; Cl, 
Confidence interval; PPI, Proton pump Inhibitor; H. pylori, Helicobacter Pylori. 
   HR* 95% Cl* p-Value* 
Drug use 
vs. non-use 
Non-use 1.00 - - 
PPI 1.25 1.13-1.37 5.7·10-6 
H. Pylori 
Negative 1.00 - - 
Positive  2.99 2.38-3.75 2.22·10-16 
Region of 
residence 
South-East Norway 1.00 - - 
Western Norway 1.22 1.11-1.35 5.13·10-5 
Mid-Norway 1.24 1.11-1.38 1.11·10-4 
Northern Norway 1.43 1.27-1.61 1.56·10-9 
Unknown/missing region 0.19 0.10-0.37 5·10-7 
Education 
Primary/lower secondary 1.00 - - 
Upper secondary 0.84 0.77-0.91 3.91·10-5 
Undergraduate 0.63 0.55-0.71 3.83·10-13 
Graduate/postgraduate 0.54 0.44-0.66 5.12·10-10 
No education/missing 1.14 0.86-1.51 0.348 
Comorbidity 
No 1.00 - - 
Yes 1.08 1.04-1.12 7.77·10-5 
Other drug use 
No 1.00 - - 
Yes 1.03 0.94-1.13 0.477 
*The presented results are adjusted for H2RA use 
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6 Discussion 
We have presented the results for our population-based nested case-control study 
investigating the association between the use of PPI and H2RA and the risk of gastric cancer 
involving 33 847 residents in Norway. To our knowledge, the associations between the use of 
PPI and H2RA and gastric cancer risk have not been investigated in a population-based study 
in Norway before.   
6.1 Discussion of results 
We observed an association with increased risk of gastric cancer among PPI users and long-
term PPI users in Norway. However, we did not observe any dose-response relationship 
between PPI use and gastric cancer risk. The corresponding results for H2RA use, long-term 
use and dose-response relationship were not significant. When comparing PPI use directly 
with H2RA use in an active comparator design, we did not observe a significant association 
between PPI use and the risk of gastric cancer.  
Our significant results for long-term PPI use and gastric cancer risk were similar to previous 
observational studies. As an example, the Swedish study observed an increased risk of gastric 
cancer among individuals who underwent maintenance therapy of PPI defined as cumulative 
DDD of at least 180 days, while the authors in Cheung´s study found that the risk of gastric 
cancer was still increased after H. Pylori eradication therapy among long-term PPI users (17, 
21). As for the PPI use and gastric cancer risk, our result is consistent with a recent 
observational study from the United Kingdom where they observed an increased risk of 
gastric cancer among PPI users (23). 
The most plausible hypothesis for establishing a causal relationship between long-term PPI 
use and development of gastric cancer is hypergastrinemia (41). Hypergastrinemia is a 
compensatory increase in gastrin production as a response to the suppression of gastric acid. 
A recent study found a significant increase of serum gastrin after a four-day PPI-therapy 
among healthy volunteers (42). The increased level of gastrin is associated with the formation 
of NETs (28). 
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In addition, our results of dose-response relationship between PPI use and the risk of gastric 
cancer is consistent with the recent study from the United Kingdom where they also did not 
observe a dose-response relationship for PPI (23). In contrast, Cheung´s study observed a 
significant dose-response relationship between PPI use and gastric cancer risk. However, PPI 
users were almost 10 years older than non-users in his study. Increased age is an important 
risk factor for gastric cancer and might have influenced his results (43). Moreover, the study 
population in Cheung’s study was mainly of Chinese origin. This could imply that Cheung´s 
finding may not be applicable to other ethnic groups as Asians are at higher risk of gastric 
cancer compared to the western population (44). However, the lack of a dose-response 
relationship for PPI in our study could also indicate that confounding by indication is 
influencing our significant result for (long-term) PPI use and gastric cancer risk.  
Our corresponding results for H2RA use, long-term use and dose-response relationship were 
not associated with gastric cancer risk which was consistent with findings from the Danish 
and Swedish study (21, 22). A possible explanation is that PPI is a more potent drug and may 
give more side effects compared to H2RA. In addition, we only identified 2098 (6%) H2RA 
users in our study and this leads to a lower power for the analysis compared to the association 
analysis on PPI use and the risk of gastric cancer. Yet, the recent observational study from the 
United Kingdom found that H2RA use was significantly associated with an increased risk of 
gastric cancer (OR=1.44, 95% Cl 1.16-1.80). In contrast to the Danish and Swedish study, the 
recent study from the United Kingdom was not adjusted for H. Pylori (23).  
The Danish and Cheung´s study were also consistent with our findings of the active 
comparator analysis as none of us did observe a significant difference in the risk of gastric 
cancer when comparing PPI users to H2RA users (17, 22). To observe a significant impact on 
the risk of gastric cancer when comparing PPI users to non-users, but not when comparing to 
H2RA users signifies that the indication has influenced the results of PPI users vs. non-users 
analysis. Thus, this could mean that our observed association between PPI (long-term) use 
and the risk of gastric cancer is influenced by confounding by indication. As an example, 
diseases such as H. Pylori and PUD are indications for PPI use and important risk factors in 
developing gastric cancer (45).  
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In our study we also observed a significant impact of a positive H. Pylori result on the risk of 
gastric cancer among PPI users. This was not surprising as H. Pylori is heavily associated 
with gastric cancer (46). This also indicates the importance of identifying individuals with H. 
Pylori when trying to disentangle the effect of H. Pylori on the association of drug use and 
the risk of gastric cancer. However, we only identified 427 (1%) individuals with positive H. 
Pylori in our study with a higher percentage of H. Pylori among cases (4%) compared to 
controls (1%). Although the exact prevalence of H. Pylori in Norway is unknown, it is 
estimated to be approximately 10-40% (47).  
We therefore believe that we were not able to identify all positive H. Pylori individuals. The 
main reason is that we identified H. Pylori by individuals who had undergone eradication 
therapy instead of endoscopy with biopsy, which is the preferable method to diagnose H. 
Pylori (48). Second, when we first tried to identify individuals who received eradication 
therapy (2 antibiotics + PPI) on prescription, we only managed to identify approximately 100 
individuals with positive H. Pylori between 2004 and 2015. We then chose to exclude PPI 
from our inclusion criteria and only included individuals who received two of three antibiotics 
used in eradication therapy. The same method was used in the Danish study (22). In this case, 
we identified more cases of H. Pylori, but most likely not all cases of H. Pylori in Norway. 
Finally, individuals who underwent eradication therapy in hospital were not included as 
NorPD only covers the ambulatory care.  
Not being able to identify all individuals with treated or untreated H. Pylori infection at the 
time could potentially influence our findings, because H. Pylori is an important confounding 
factor on the association between PPI and gastric cancer.  
Moreover, we observed that residency in Northern Norway in particular, but also in Mid and 
Western Norway was associated with an increased risk of gastric cancer among PPI users 
compared to South-East of Norway. We believe that residency partly reflects the prevalence 
of H. Pylori in different regions. Relevant lifestyle factors such as diet also differs across 
Norway. A Norwegian study have suggested that there are different food patterns in Norway 
and this pattern may reflect where in the country you live. As an example, the Norwegian 
coastline has easy access to fish and thus a higher fish consumption in contrast to the inner 
parts of Norway (49). 
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We also know that the majority of PPI users since 2004 are living in Northern Norway (1) 
although we only identified 807 (13%) PPI users from the North. The frequent use of PPI 
might also support a higher prevalence of H. Pylori in the North and might explain the 
increased risk of gastric cancer.  
Another explanation of the residency factor is that the distance to the nearest health institution 
for individuals living in the North is usually longer compared to South-East, West and Mid of 
Norway. This could make the threshold for seeking medical attention higher in the North and 
might explain the increased risk of gastric cancer. However, we were unable to adjust for 
smoking, alcohol intake, obesity measured by body mass index and genetic factors which are 
risk factors for developing gastric cancer (45, 50, 51). 
Regarding education, we observed that having a higher educational level (upper secondary or 
higher) was associated with a decreased risk of gastric cancer. Similar findings were found in 
Lagergren et al study where they suggested that higher educational level makes people more 
health-conscious (52). 
Furthermore, it is not unusual to use PPI in combination or supplement with other drug 
groups such as antibiotics (eradication therapy for H. pylori) or NSAIDs to prevent ulcer (one 
of the indications for PPIs). Using other drugs in combination with PPI/H2RA could impact 
our results. As an example, NSAIDs have been shown to be associated with a decreased risk 
of gastric cancer (53). Despite that we identified that 84% of PPI and H2RA users used other 
drugs than PPI or H2RA, we did not observe a significant impact on gastric cancer for this 
group. 
In summary, we found an association between PPI use and long-term PPI use and the 
increased risk of gastric cancer. However, we did not find a dose-response relationship, which 
therefore supports the rationale that well known risk factors such as H. Pylori were associated 
with both PPI use and increased risk of gastric cancer (confounding by indication). 
Furthermore, the active comparator design did not reveal any difference between PPI and 
H2RA use. This conclusion is also supported by the Danish study where they observed an 
increased risk of gastric cancer among individuals who have received more than 15 
prescriptions on PPI, but the authors concluded that their findings were likely to result from 
confounding by indication (22).  
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Systematic reviews of RCTs did not suggest an association between long-term PPI use and 
the risk of gastric premalignant lesions. However, the numbers of included participants were 
small, and the follow-up time was relatively short (maximum 36 months) in the clinical 
studies (54). 
6.2 Discussion of methods 
We acknowledge that our observational study reveals statistical association only, and not 
implying a causal relationship between PPI use and the risk of gastric cancer due to unknown 
or unobserved confounders. However, observational studies are able to assess research 
questions in an unselected population in contrast to experimental studies such as RCTs and 
are thus an important supplement to RCTs. 
Our study had the advantage of collecting information on the Norwegian population based on 
high quality registry data, which includes complete data on drug prescription and cancer 
diagnosis. This method will counteract for information and recall bias as individuals do not 
have to report their own drug use or cancer diagnosis. As a result, we included all Norwegian 
individuals with a primary diagnosis of gastric cancer from 2007 to 2015, and thus avoiding 
selection bias. 
Furthermore, we took reverse causation into consideration and introduced a 12-month lag 
time while previous studies have operated with 6 to 24 month-lag time (17, 21-23). However, 
a recent study suggested that 6 months lag was sufficient (55). 
A limitation of our study was that we did not have information on PPI and H2RA use before 
2004. Not having information on drug use before 2004 potentially weakens the associations 
found in our study as some of the non-users could have been former PPI or H2RA users. We 
were also not able to include individuals who have used PPI or H2RA over-the-counter. 
Moreover, NorPD does not provide information on compliance. This means that there is no 
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7 Conclusion 
To conclude, our findings do not support a causal relationship between PPI use and the risk of 
gastric cancer in Norway. However, we cannot rule out this hypothesis. Observational studies 
adjusted for relevant confounders, in particular H. Pylori and PUD, or larger clinical studies 
with a longer follow-up are needed to evaluate this hypothesis in the future.  
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